ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO243

A Novel In Vivo Model of Renal Cell Carcinoma (RCC) Angiogenesis

Session Information

Category: Onconephrology

  • 1700 Onconephrology


  • Levin-Klein, Rena, Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel
  • Rabinowitz, Grace, Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel
  • Greenberger, Shoshana, Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel
  • Beckerman, Pazit, Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel
  • Pleniceanu, Oren, Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel

Renal cell carcinoma (RCC) is the most common tumor in the kidney and currently lacks effective treatments. Remarkably, although RCC is an extremely angiogenic tumor, existing drugs aimed at inhibiting angiogenesis have shown disappointing results in patients. One potential reason for this discrepancy is the fact that most models used to dissect the molecular mechanisms of RCC angiogenesis involve transplantation of human tumor cells into mice, which results in development of host-derived vasculature, putting into question their clinical relevance. We have previously shown that combined transplantation of human kidney cells alongside human vessel forming cells into immunodeficient mice allows the generation of vascularized reno-vascular units. Herein, we aimed to develop a novel in-vivo model that will include RCC cells and vessels that are both human-derived.


We inoculated immunodefficient NOD-SCID mice with a combination of 106 fresh RCC cells and two types of human cells: (1) 5X105 Endothelial Colony Forming Cells (ECFC); (2) 5X105 Multipotent Stromal Cells (MSC), and analyzed the grafts following 3 weeks using immunostaining.


Remarkably, the grafts developed into vascularized tumor units consisting of both RCC-like tissue, expressing classical markers of the tumor (e.g., PAX2 and PAX8), as well as human, HLA-positive blood vessels, contatining CD31+ endothelium, which were seen to feed the tumor tissue.


Taken together, this model represents a new purely-human inv-vivo model that allows studying the process of RCC angiogenesis, which could facilitate the uncovering of new mechanisms governing this critical process.


  • Private Foundation Support